Body composition emerges as a key factor in brain health, according to recent research. Targeted fat reduction and muscle ...

According to recent research, astrocyte cell transplantation could revolutionize treatments for neurological disorders such ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

the researchers have now analysed the processing of GPR37 in the brain and the presence of ecto-GPR37 in the cerebrospinal fluid of patients with Parkinson's, Alzheimer's and also other ...

Lewy bodies can be present in the brains of those with Alzheimer’s and often in those with Parkinson’s as well. Early signs of this type of dementia are problems with reasoning and judgment.

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression ... Can Negatively Impact Older Adults With Alzheimer's Disease or Related Dementias Oct. 30 ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...

Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on VYGR stock, giving a Buy rating yesterday.